For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on December 16th, 2025 | 07:00 CET
Great potential in the defense sector! RENK, Hensoldt, NEO Battery Materials
Milestone at NEO Battery Materials! With the lease of its new operational battery facility, NEO Battery is now ready to start commercializing its high-performance battery technology for defense, automotive and energy sectors. The new factory eliminates the need for time-consuming and costly construction. Orders and partnerships are also already in place. It is likely only a matter of time before batteries are also used in tanks. In Germany, RENK, for example, is developing drives for vehicles weighing up to 70 tons. Analysts consider the recent sell-off in defense stocks to be exaggerated. Their current favorite is Hensoldt. However, the sensor specialist is not recommended as a buy by all experts.
Read
Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET
Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!
Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.
Read
Commented by Fabian Lorenz on December 12th, 2025 | 07:05 CET
Comeback for Volkswagen, BMW & Co.? European Lithium shares benefit from 2 megatrends!
What a comeback for German automakers in the field of electric mobility! The Volkswagen Group accounts for 4 of the top 5 best-selling vehicles in Europe. BMW impresses in tests with its new iX3, which heralds a "new class" for the Munich-based company. The former market leader, Tesla, no longer plays a significant role, partly due to Elon Musk. The current challenger in Europe is now BYD, although the Chinese stock's chart remains far from convincing. In contrast, European Lithium's stock has exploded by almost 400% in the current year. Rare earths and lithium for Europe are driving the price.
Read
Commented by Fabian Lorenz on December 12th, 2025 | 06:55 CET
Buy these stocks now?! Bayer, Gerresheimer, WashTec!
Bayer is undoubtedly one of the positive surprises of 2025 on the German stock market. Operations are running smoothly for the Leverkusen-based company, particularly in the pharmaceutical sector. And next year, the glyphosate disaster could also come to an end. Analysts have now raised their price target. WashTec shares are still at the beginning of an upward trend. Growth, improved margins, a dividend yield of 5%, and a share buyback program continue to argue in favor of buying the stock. Analysts share this opinion. Experts do not yet see the time as right to buy Gerresheimer shares. Although the stock appears to have bottomed out, investors are still advised to wait.
Read
Commented by Fabian Lorenz on December 11th, 2025 | 07:15 CET
DO NOT PANIC! Almonty, Standard Lithium, and DroneShield
Commodity gem Almonty experienced a significant price setback on Tuesday. But yesterday's recovery shows that there is no reason to panic. The Company is on its way to becoming a tungsten superpower. CEO Lewis Black left no doubt about this during his latest presentation to investors. According to him, the tungsten spot price could rise to USD 1,000 per MTU. Analysts expect significantly less, and Almonty is already achieving strong margins at USD 300. The fact that investors can react very sensitively after massive price gains was demonstrated by DroneShield's stock. But now the recovery rally is underway. Things are also happening at Standard Lithium. The Americans appear to be well on their way to securing billions of USD for the construction of their first lithium mine.
Read
Commented by Fabian Lorenz on December 11th, 2025 | 07:00 CET
Big news at TUI! Up to 16% dividend with Vonovia and RE Royalties shares!
Big news at TUI. Things had been quiet around TUI shares in recent weeks, but the Company has now catapulted itself back into the headlines. For the first time since the coronavirus pandemic, TUI plans to pay a dividend again. The stock reacted surprisingly weakly to the news. In contrast, the share of dividend hidden gem RE Royalties finally appears to be gaining traction. A dividend yield of around 16% is an attractive entry point! Vonovia shareholders currently receive a stable dividend yield of around 5%. The stock has been somewhat disappointing this year. However, analysts remain optimistic and have high hopes for the security.
Read
Commented by Fabian Lorenz on December 10th, 2025 | 07:25 CET
Nordex strong! D-Wave with an important date! JPMorgan gives Finexity a tailwind!
Stock market newcomer Finexity is still struggling with its revolutionary business model. The Company operates a trading platform for tokenized assets. The fact that JPMorgan is now also entering the tokenization sector is a real bombshell. This should benefit the entire industry, including Finexity, especially since the Hamburg-based company is collaborating with a savings bank in a pilot project. This offers the opportunity to reach over 45 million potential customers. Nordex has won over customers in France and Belgium. The German company will supply them with wind turbines in 2026 and 2027. Can the stock break out? D-Wave has made substantial gains in recent days. An important event is coming up for the quantum pioneer in January.
Read
Commented by Fabian Lorenz on December 10th, 2025 | 07:00 CET
Defense stocks are RISING! The US is leaving Europe on its own! Rheinmetall, Hensoldt, and Antimony Resources!
Investors are once again snapping up defense stocks. On the one hand, peace in Ukraine seems unlikely in the foreseeable future. On the other hand, Europe can no longer rely on the US. Rheinmetall and Hensoldt are therefore in high demand. The shares of both companies have gained ground in recent days and have received additional tailwind from orders. Defense companies such as Rheinmetall and Hensoldt would likely face major problems without antimony. Nevertheless, this critical metal is relatively unknown among investors. Here, too, China determines supply. This makes Antimony Resources interesting for investors. After strong share price gains, the stock has recently consolidated. This offers an entry opportunity before the first resource estimate is published shortly.
Read
Commented by Fabian Lorenz on December 9th, 2025 | 07:10 CET
100% price potential! Bayer, Steyr Motors, and gold gem Kobo Resources
Kobo Resources shares have awakened in the past week. The gold explorer gained 20%, and according to analysts, this is far from over. They see the fair value of the mining projects at more than 100% above the current company value. Bayer shares have performed particularly well this year. Very few would have thought a price increase of over 70% in 2025 possible. Now, however, analysts are putting the brakes on the euphoria. And what about Steyr Motors? The shares of the specialty engine manufacturer have shifted into high gear again in recent weeks. Analysts are enthusiastic about the technology in this niche market. They see significant sales growth and rising margins.
Read
Commented by Fabian Lorenz on December 8th, 2025 | 07:15 CET
RENK better than HENSOLDT? Risk at NOVO NORDISK! Billion-dollar opportunity with RZOLV Technologies!?
Is RENK's stock better than Hensoldt's? That is what analysts are saying. According to them, the transmission specialist is attractively valued at the current level. Hensoldt, on the other hand, is having problems converting its order backlog into revenue growth, leading to a significant reduction in its price target. In contrast, RZOLV Technologies shares have enormous upside potential. The Company aims to replace a toxic chemical used in gold extraction, thereby opening up a billion-dollar market. Development is nearly complete, and patents have been filed. In just a few months, RZOLV could become a hot takeover candidate. Meanwhile, takeovers currently appear to be a way for Novo Nordisk to replenish its drug pipeline, with the Danish company taking risks worth billions - Pfizer, take note.
Read